FINWIRES · TerminalLIVE
FINWIRES

Hanmi Pharm Grants Eli Lilly Worldwide License for Intestinal Growth Drug; Shares Rise 6%

By

Hanmi Pharm (KRX:128940) granted Eli Lilly worldwide exclusive rights to develop, produce, and market the South Korean drug company's sonefpeglutide biologic drug candidate, according to a Monday news release in Seoul.

The rights do not cover Korea, according to Hanmi.

Hanmi is set to receive a $75 million upfront payment from the U.S. drug company and an additional $1.19 billion in milestone payments from clinical development, regulatory approval, and commercialization.

The South Korean drug company will also be eligible for royalties following the launch.

Sonefpeglutide is a long-acting glucagon-like peptide 2 or GLP-2 that helps with intestinal growth. GLP-2 obtained approval for short bowel syndrome.

Shares rose 6% during afternoon trading on Monday.

Related Articles

Asia

Tianyu Semiconductor Wins China Nod for H-Share Full Circulation

Guangdong Tianyu Semiconductor (HKG:2658) received acceptance from the China Securities Regulatory Commission for its proposed H-share full circulation plan, according to a Friday Hong Kong bourse filing.The application covers the conversion of 334.3 million unlisted shares held by participating shareholders into Hong Kong-listed shares.Shares of the firm were down over 2% in Monday morning trade.

HKG:2658
Asia

Market Chatter: Big Caring Targets About MYR3 Billion Via Malaysia IPO

Big Caring Group is preparing for a stock market debut that could raise as much as 3 billion ringgit ($750 million), positioning the pharmacy retailer among Malaysia's largest IPOs in recent years, Bloomberg News reported Friday, citing people with knowledge of the matter.The pharmacy chain, backed by private equity firm Creador, is aiming to list by October. It plans to offer up to 25.5% of its enlarged share capital, with part of the proceeds to be used to repay debt. The size and timing of the IPO could still change.Big Caring runs 626 outlets across Malaysia under brands including Big Pharmacy and Caring Pharmacy. Creador, which holds roughly 34% of the company, plans to sell up to 14.8% of its stake in the offering. The company did not respond to Bloomberg's request for a comment, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

FTSE Bursa Malaysia KLCI
Asia

AMTD Idea Arm Acquires Majority Stake in Malaysian Upper View Regalia Hotel

AMTD Idea (SGX:HKB) said The Generation Essentials Group has acquired super majority interests in the Upper View Regalia Hotel in Kuala Lumpur, Malaysia, for $38 million, according to a Friday filing with the Singapore Exchange.The property comprises 129 guest rooms and serves the hospitality and lifestyle needs of global citizens and local communities.Following the acquisition, the conglomerate's hospitality portfolio is nearing 1,000 rooms.The Generation Essentials Group is a subsidiary of New York-listed AMTD Digital.

SGX:HKB